Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Intravenous Doripenem in Complicated Lower Urinary Tract Infection or Pyelonephritis
2004-004573-29Phase 3Completed
- Sponsor
- Peninsula Pharmaceuticals
- Start
- Dec 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of doripenem in complicated urinary tract infection (cUTI) and pyelonephritis, sponsored by Peninsula Pharmaceuticals. Primary endpoint: Microbiological response at 6–9 days post-therapy. Started Dec 2004; status: completed.
02
Drugs
doripenem
03
Conditions
complicated urinary tract infection (cUTI)pyelonephritis
Beyond the preview
Go deeper on 2004-004573-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004573-29.